NuCana plc NCNA
NuCana plc (Nasdaq: NCNA) is an oncology drug developer. Its lead program, NUC-7738, is in Phase 2 for PD-1 inhibitor-resistant melanoma (in combination with pembrolizumab); advanced solid tumors (Phase 1 monotherapy). Its next catalyst on record is NUC-7738: Report data from Phase 2 expansion study in PD-1 inhibitor-resistant melanoma (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NUC-7738 — Report data from Phase 2 expansion study in PD-1 inhibitor-resistant melanoma (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NUC-7738 | PD-1 inhibitor-resistant melanoma (with pembrolizumab) | small molecule | Phase 2 |
| NUC-3373 | Advanced colorectal cancer and other solid tumors (combinations) | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.